ESC 365 - DAPA HF - The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

ESC Premium Access

DAPA HF - The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

Session: Hot Line Session 1

Topic: European Society of Cardiology, Other

Speaker: Professor J. McMurray (Glasgow, GB)

Event: ESC CONGRESS 2019

Congress Presentation

About the speaker

Professor John J V McMurray

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

84 presentations

6 followers

11 more presentations in this session

THEMIS - Main Results of the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study

Speaker: Professor D. Bhatt (Boston, US)

THEMIS-PCI: Ticagrelor in Patients with Diabetes and Stable Coronary Artery Disease with a History of Prior Percutaneous Coronary Intervention

Speaker: Professor P. Steg (Paris, FR)

Discussant review - THEMIS/THEMIS-PCI

Speaker: Professor C. Baigent (Oxford, GB)

Questions from the audience and discussion

PARAGON-HF - Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Speaker: Professor S. Solomon (Boston, US)

Access the full session

Hot Line Session 1

Speakers: Professor J. McMurray, Professor D. Bhatt, Professor P. Steg, Professor C. Baigent, Professor S. Solomon

About the event

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Related content

Open Access

Definition and pathophysiological mechanisms of HFpEF.

29 August 2021

ESC Premium Access

Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)

28 August 2021

Open Access

New recommendations for the treatment of HFrEF.

27 August 2021

ESC 365 is supported by